SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-11-3442. This Article Full Text (PDF) All Versions of this Article: 2002-11-3442v1 101/11/4279    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mounier, N. Articles by Coiffier, B. Search for Related Content PubMed PubMed Citation Articles by Mounier, N. Articles by Coiffier, B. Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted November 14, 2002 Accepted January 19, 2003 Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Nicolas Mounier*, Josette Briere, Christian Gisselbrecht, Jean-Francois Emile, Pierre Lederlin, Catherine Sebban, Francoise Berger, Andre Bosly, Pierre Morel, Herve Tilly, Reda Bouabdallah, Felix Reyes, Philippe Gaulard, and Bertrand Coiffier ERM0220, Hopital Saint Louis, Paris, France Service d'Anatomie Pathologique, Hopital Paul Brousse, Villejuif, France Service de Medecine A, Hopital Brasbois, Nancy, France Service d'Hematologie, Centre Leon Berard, Lyon, France Service d'Anatomie Pathologique, Hopital Lyon Sud, Pierre Benite, France Service d'Hematologie, Clinique Mont Godine, Yvoir, Belgium Service d'Hematologie, Hopital Dr Schaffner, Lens, France Service d'Hematologie, Centre Henry BequerelBerard, Rouen, France Service d'Hematologie, Institut Paoli Calmette, Marseille, France Service d'Hematologie, Hopital Henri Mondor, Creteil, France Departement de Pathologie, Hopital Henri Mondor, Creteil, France Service d'Hematologie, Hopital Lyon Sud, Pierre Benite, France * Corresponding author; email: nicolas.mounier{at}sls.ap-hop-paris.fr. In DLBCL, the combination of rituximab and CHOP (R-CHOP) has been proved more beneficial than CHOP alone for the treatment of elderly patients. Bcl-2 protein expression has been associated with poor prognosis in DLBCL patients. To establish, in vivo, whether or not rituximab reduces bcl-2 associated treatment failure, we studied bcl-2 expression and clinical outcome in patients included in the Groupe d'Etude des Lymphomes de l'Adulte (GELA) LNH-98-5 trial. Patients aged between 60 and 80 years were randomized to receive 8 cycles of either CHOP or R-CHOP every 3 weeks. Of the 399 patients included, 292 with histologically proven DLBCL had material available for bcl-2 study. Tumors were considered positive when at least 50% of tumor cells expressed bcl-2 protein. There were 193 (66%) bcl-2-positive patients and 99 (34%) bcl-2-negative patients. The response rates for R-CHOP and CHOP were respectively 78 and 60% (P=0.01) in bcl-2-positive patients and 76 and 73% (P=0.7) in bcl-2-negative patients. At a median of 2 years' follow-up, R-CHOP was significantly associated with a better overall survival than CHOP in bcl-2-positive patients (67 ± 9% vs 48 ± 11%, P=0.004) but not in bcl-2-negative patients (72 ± 12% vs 67 ± 14%, P=0.6). In addition, R-CHOP was associated with significantly better event-free-survival than CHOP in bcl-2-positive patients (58 ± 10% vs 32 ± 10%, p<0.001) but not in bcl-2-negative patients (60 ± 13% vs 40 ± 15%, P=0.13). Multivariate analysis confirmed the significant benefit for survival and event-free-survival of R-CHOP in bcl-2 positive patients. These results suggest that rituximab is able to prevent chemotherapy failure in bcl-2 positive patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Targeting CD20 Jane N. Winter Blood 2003 101: 4227. [Full Text] [PDF] This article has been cited by other articles: C. Copie-Bergman, P. Gaulard, K. Leroy, J. Briere, M. Baia, J.-P. Jais, G. A. Salles, F. Berger, C. Haioun, H. Tilly, et al. Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study J. Clin. Oncol., November 20, 2009; 27(33): 5573 - 5579. [Abstract] [Full Text] [PDF] A. Bari, L. Marcheselli, S. Sacchi, R. Marcheselli, S. Pozzi, P. Ferri, E. Balleari, P. Musto, S. Neri, M. A. Aloe Spiriti, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story Ann. Onc., November 17, 2009; (2009) mdp531v1. [Abstract] [Full Text] [PDF] R. Seki, K. Ohshima, T. Fujisaki, N. Uike, F. Kawano, H. Gondo, S. Makino, T. Eto, Y. Moriuchi, F. Taguchi, et al. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab Ann. Onc., November 4, 2009; (2009) mdp481v1. [Abstract] [Full Text] [PDF] H.-W. Bernd, M. Ziepert, C. Thorns, W. Klapper, H.-H. Wacker, M. Hummel, H. Stein, M.-L. Hansmann, G. Ott, A. Rosenwald, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials Haematologica, November 1, 2009; 94(11): 1569 - 1580. [Abstract] [Full Text] [PDF] J. W. Sweetenham, B. Goldman, M. L. LeBlanc, J. R. Cook, R. R. Tubbs, O. W. Press, D. G. Maloney, R. I. Fisher, L. M. Rimsza, R. M. Braziel, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study Ann. Onc., October 29, 2009; (2009) mdp460v1. [Abstract] [Full Text] [PDF] E C Obermann, M Csato, S Dirnhofer, and A Tzankov BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma J. Clin. Pathol., October 1, 2009; 62(10): 903 - 907. [Abstract] [Full Text] [PDF] N. A. Johnson, K. J. Savage, O. Ludkovski, S. Ben-Neriah, R. Woods, C. Steidl, M. J. S. Dyer, R. Siebert, J. Kuruvilla, R. Klasa, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Blood, September 10, 2009; 114(11): 2273 - 2279. [Abstract] [Full Text] [PDF] E. Brusamolino First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions Haematologica, September 1, 2009; 94(9): 1194 - 1198. [Full Text] [PDF] Y. H. Park, S. K. Sohn, J. G. Kim, M.-H. Lee, H. S. Song, M. K. Kim, J. S. Jung, J.-J. Lee, H. J. Kim, and D. H. Kim Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy Clin. Cancer Res., March 15, 2009; 15(6): 2107 - 2115. [Abstract] [Full Text] [PDF] M. Y. Zhao, A. Auerbach, A. M. D'Costa, A. P. Rapoport, A. M. Burger, E. A. Sausville, S. A. Stass, F. Jiang, A. M. Sands, N. Aguilera, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy Clin. Cancer Res., March 1, 2009; 15(5): 1708 - 1720. [Abstract] [Full Text] [PDF] D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) J. Clin. Pathol., February 1, 2009; 62(2): 128 - 138. [Abstract] [Full Text] [PDF] D. de Jong, A. Koster, A. Hagenbeek, J. Raemaekers, D. Veldhuizen, S. Heisterkamp, J. P. de Boer, and M. van Glabbeke Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols Haematologica, January 1, 2009; 94(1): 70 - 77. [Abstract] [Full Text] [PDF] M. Ageberg, J. Linderoth, O. Linden, M. Jerkeman, and K. Drott Simvastatin Sensitizes Bcl-2-Negative DLBCL Cell Lines to CHOP: A Finding with Possible Clinical Implications for Treatment of Bcl-2-Negative DLBCL? Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 5044 - 5044. [Abstract] D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Ann. Onc., November 1, 2008; 19(11): 1921 - 1926. [Abstract] [Full Text] [PDF] L. M. Rimsza, M. L. LeBlanc, J. M. Unger, T. P. Miller, T. M. Grogan, D. O. Persky, R. R. Martel, C. M. Sabalos, B. Seligmann, R. M. Braziel, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP Blood, October 15, 2008; 112(8): 3425 - 3433. [Abstract] [Full Text] [PDF] K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al. Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., October 1, 2008; 26(28): 4587 - 4594. [Abstract] [Full Text] [PDF] B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF] M. Yamaguchi, N. Nakamura, R. Suzuki, Y. Kagami, M. Okamoto, R. Ichinohasama, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients Haematologica, August 1, 2008; 93(8): 1195 - 1202. [Abstract] [Full Text] [PDF] R. Malumbres, J. Chen, R. Tibshirani, N. A. Johnson, L. H. Sehn, Y. Natkunam, J. Briones, R. Advani, J. M. Connors, G. E. Byrne, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Blood, June 15, 2008; 111(12): 5509 - 5514. [Abstract] [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724. [Abstract] [Full Text] [PDF] J. W. Friedberg Bak to death with chemotherapy Blood, June 1, 2008; 111(11): 5263 - 5264. [Full Text] [PDF] F. Jardin, P. Ruminy, J.-P. Kerckaert, F. Parmentier, J.-M. Picquenot, S. Quief, C. Villenet, G. Buchonnet, M. Tosi, T. Frebourg, et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas Haematologica, April 1, 2008; 93(4): 543 - 550. [Abstract] [Full Text] [PDF] P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 Ann. Onc., March 1, 2008; 19(3): 560 - 565. [Abstract] [Full Text] [PDF] G. A. Ulaner, P. M. Colletti, and P. S. Conti B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience Radiology, March 1, 2008; 246(3): 895 - 902. [Abstract] [Full Text] [PDF] O. Determann, E. Hoster, G. Ott, H. Wolfram Bernd, C. Loddenkemper, M. Leo Hansmann, T. E. F. Barth, M. Unterhalt, W. Hiddemann, M. Dreyling, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group Blood, February 15, 2008; 111(4): 2385 - 2387. [Abstract] [Full Text] [PDF] Y. Natkunam, P. Farinha, E. D. Hsi, C. P. Hans, R. Tibshirani, L. H. Sehn, J. M. Connors, D. Gratzinger, M. Rosado, S. Zhao, et al. LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab J. Clin. Oncol., January 20, 2008; 26(3): 447 - 454. [Abstract] [Full Text] [PDF] D. Daniel, B. Yang, D. A. Lawrence, K. Totpal, I. Balter, W. P. Lee, A. Gogineni, M. J. Cole, S. F. Yee, S. Ross, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts Blood, December 1, 2007; 110(12): 4037 - 4046. [Abstract] [Full Text] [PDF] S. Prakash and S. H Swerdlow Nodal aggressive B-cell lymphomas: a diagnostic approach J. Clin. Pathol., October 1, 2007; 60(10): 1076 - 1085. [Abstract] [Full Text] [PDF] F. Grange, M. Beylot-Barry, P. Courville, E. Maubec, M. Bagot, B. Vergier, P. Souteyrand, L. Machet, S. Dalac, E. Esteve, et al. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Clinicopathologic Features and Prognostic Analysis in 60 Cases Arch Dermatol, September 1, 2007; 143(9): 1144 - 1150. [Abstract] [Full Text] [PDF] J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF] Y.-Y. Liu, C. Leboeuf, J.-Y. Shi, J.-M. Li, L. Wang, Y. Shen, J.-F. Garcia, Z.-X. Shen, Z. Chen, A. Janin, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 339 - 344. [Abstract] [Full Text] [PDF] J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al. Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma Haematologica, June 1, 2007; 92(6): 778 - 783. [Abstract] [Full Text] [PDF] H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood, June 1, 2007; 109(11): 4930 - 4935. [Abstract] [Full Text] [PDF] H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy Ann. Onc., May 1, 2007; 18(5): 931 - 939. [Abstract] [Full Text] [PDF] D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al. Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium J. Clin. Oncol., March 1, 2007; 25(7): 805 - 812. [Abstract] [Full Text] [PDF] C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF] L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood, March 1, 2007; 109(5): 1857 - 1861. [Abstract] [Full Text] [PDF] K. Dunleavy, R. E. Davis, O. Landgren, L. M. Staudt, and W. H. Wilson BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? Blood, January 15, 2007; 109(2): 843 - 844. [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, N. Grant, M. Shovlin, S. Steinberg, M. Raffeld, L. Staudt, E. S. Jaffe, and J. Janik DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6- Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 206 - 206. [Abstract] [Full Text] [PDF] P. Farinha, L. Sehn, B. Skinnider, J. M. Connors, and R. D. Gascoyne Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 816 - 816. [Abstract] [Full Text] [PDF] D. H. Kim, H. D. Jung, J. G. Kim, J.-J. Lee, D.-H. Yang, Y. H. Park, Y. R. Do, H. J. Shin, M. K. Kim, M. S. Hyun, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma Blood, October 15, 2006; 108(8): 2720 - 2725. [Abstract] [Full Text] [PDF] G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4135 - 4142. [Abstract] [Full Text] [PDF] C. Moskowitz Is it time to stop treating subsets of DLBCL with R-CHOP? Blood, June 1, 2006; 107(11): 4197 - 4198. [Full Text] [PDF] J. N. Winter, E. A. Weller, S. J. Horning, M. Krajewska, D. Variakojis, T. M. Habermann, R. I. Fisher, P. J. Kurtin, W. R. Macon, M. Chhanabhai, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood, June 1, 2006; 107(11): 4207 - 4213. [Abstract] [Full Text] [PDF] A.-M. Tsimberidou, S. O'Brien, I. Khouri, F. J. Giles, H. M. Kantarjian, R. Champlin, S. Wen, K.-A. Do, S. C. Smith, S. Lerner, et al. Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation J. Clin. Oncol., May 20, 2006; 24(15): 2343 - 2351. [Abstract] [Full Text] [PDF] A. Tzankov, A. Gschwendtner, F. Augustin, M. Fiegl, E. C. Obermann, S. Dirnhofer, and P. Went Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin. Cancer Res., April 1, 2006; 12(7): 2125 - 2132. [Abstract] [Full Text] [PDF] I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF] J. Iqbal, V. T. Neppalli, G. Wright, B. J. Dave, D. E. Horsman, A. Rosenwald, J. Lynch, C. P. Hans, D. D. Weisenburger, T. C. Greiner, et al. BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 961 - 968. [Abstract] [Full Text] [PDF] L. H. Sehn Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 295 - 302. [Abstract] [Full Text] [PDF] S. Camilleri-Broet, E. Criniere, P. Broet, V. Delwail, K. Mokhtari, A. Moreau, M. Kujas, M. Raphael, W. Iraqi, C. Sautes-Fridman, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases Blood, January 1, 2006; 107(1): 190 - 196. [Abstract] [Full Text] [PDF] K. Leroy, J.-P. Jais, C. Haioun, D. Rickman, A. de Reynies, T. Molina, B. Coiffier, F. Berger, C. Gisselbrecht, J. Briere, et al. Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 159 - 159. [Abstract] L. D. Kaplan, J. Y. Lee, R. F. Ambinder, J. A. Sparano, E. Cesarman, A. Chadburn, A. M. Levine, and D. T. Scadden Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood, September 1, 2005; 106(5): 1538 - 1543. [Abstract] [Full Text] [PDF] C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF] M. I. Vega, A. R. Jazirehi, S. Huerta-Yepez, and B. Bonavida Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF-{kappa}B Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively J. Immunol., August 15, 2005; 175(4): 2174 - 2183. [Abstract] [Full Text] [PDF] J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF] J. C. Reed and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood, July 15, 2005; 106(2): 408 - 418. [Abstract] [Full Text] [PDF] Y. Natkunam, I. S. Lossos, B. Taidi, S. Zhao, X. Lu, F. Ding, A. S. Hammer, T. Marafioti, G. E. Byrne Jr, S. Levy, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation Blood, May 15, 2005; 105(10): 3979 - 3986. [Abstract] [Full Text] [PDF] S. J. Horning In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3162 - 3163. [Full Text] [PDF] A. P Levene, G. Singh, and C. Palmieri Therapeutic monoclonal antibodies in oncology J R Soc Med, April 1, 2005; 98(4): 146 - 152. [Full Text] [PDF] I. F. Khouri, R. M. Saliba, C. Hosing, G.-J. Okoroji, S. Acholonu, P. Anderlini, D. Couriel, M. De Lima, M. L. Donato, L. Fayad, et al. Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas J. Clin. Oncol., April 1, 2005; 23(10): 2240 - 2247. [Abstract] [Full Text] [PDF] J. J. F. Muris, S. A. G. M. Cillessen, W. Vos, I. S. van Houdt, J. A. Kummer, J. H. J. M. van Krieken, N. M. Jiwa, P. M. Jansen, H. C. Kluin-Nelemans, G. J. Ossenkoppele, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas Blood, April 1, 2005; 105(7): 2916 - 2923. [Abstract] [Full Text] [PDF] J. O. Armitage Defining the Stages of Aggressive Non-Hodgkin's Lymphoma -- A Work in Progress N. Engl. J. Med., March 24, 2005; 352(12): 1250 - 1252. [Full Text] [PDF] J. W. Sweetenham Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease Hematology, January 1, 2005; 2005(1): 252 - 259. [Abstract] [Full Text] [PDF] E. Paszkiewicz-Kozik, O. Mioduszewska, I. Federowicz, E. Kraszewska, E. Kulczycka, K. Domanska-Czyz, B. Ostrowska, J. Romejko-Jarosinska, M. Osowiecki, and J. A. Walewski Predictive Value of Bcl-2 and Bcl-6 Protein Expression in Diffuse Large B-Cell Lymphoma Patients from a Single Institution. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 4546 - 4546. [Abstract] [Full Text] G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF] B. D. Cheson What Is New in Lymphoma? CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272. [Abstract] [Full Text] [PDF] B. Coiffier, G. Salles, M. Pfreundschuh, and M. Loeffler Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma Blood, September 1, 2004; 104(5): 1584 - 1586. [Full Text] [PDF] J. W. Friedberg Developing New Monoclonal Antibodies for Aggressive Lymphoma: A Challenging Road in the Rituximab Era Clin. Cancer Res., August 15, 2004; 10(16): 5297 - 5298. [Full Text] [PDF] M. Voulgarelis, S. Giannouli, D. Anagnostou, and A. G. Tzioufas Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas Rheumatology, August 1, 2004; 43(8): 1050 - 1053. [Abstract] [Full Text] [PDF] M. Ghielmini, S.-F. H. Schmitz, S. B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M. F. Fey, D. C. Betticher, G. Martinelli, F. Peccatori, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule Blood, June 15, 2004; 103(12): 4416 - 4423. [Abstract] [Full Text] [PDF] F. Grange, T. Petrella, M. Beylot-Barry, P. Joly, M. D'Incan, M. Delaunay, L. Machet, M.-F. Avril, S. Dalac, P. Bernard, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas Blood, May 15, 2004; 103(10): 3662 - 3668. [Abstract] [Full Text] [PDF] J. A. Sparano, S. Lee, M. G. Chen, T. Nazeer, A. Einzig, R. F. Ambinder, D. H. Henry, J. Manalo, T. Li, and J. H. Von Roenn Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494) J. Clin. Oncol., April 15, 2004; 22(8): 1491 - 1500. [Abstract] [Full Text] [PDF] T. Decker, M. Oelsner, R. J. Kreitman, G. Salvatore, Q.-c. Wang, I. Pastan, C. Peschel, and T. Licht Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins Blood, April 1, 2004; 103(7): 2718 - 2726. [Abstract] [Full Text] [PDF] P. A. Volberding, K. R. Baker, and A. M. Levine Human Immunodeficiency Virus Hematology Hematology, January 1, 2003; 2003(1): 294 - 313. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020